41363-00-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Amino-5,6,7,8-tetrahydro-naphthalen-2-ol is used as a building block in the synthesis of various pharmaceutical compounds. Its unique structure and chemical properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 7-amino-5,6,7,8-tetrahydro-naphthalen-2-ol serves as a key intermediate in the production of various agrochemicals, including pesticides and herbicides. Its versatility in chemical reactions allows for the creation of effective and targeted agrochemical products.
Used in Material Science:
7-Amino-5,6,7,8-tetrahydro-naphthalen-2-ol is utilized as a raw material in the development of advanced materials for various applications. Its unique chemical properties contribute to the creation of innovative materials with improved performance characteristics.
Used as a Reagent in Organic Synthesis:
7-Amino-5,6,7,8-tetrahydro-naphthalen-2-ol is used as a reagent in organic synthesis, enabling the production of a wide range of chemical compounds. Its ability to participate in various chemical reactions makes it a valuable tool in the synthesis of complex organic molecules.
Overall, 7-amino-5,6,7,8-tetrahydro-naphthalen-2-ol is a versatile and valuable compound with applications across multiple industries, including pharmaceuticals, agrochemicals, and material science. Its unique chemical properties and structure make it an essential component in the synthesis of various products and the development of innovative materials.

InChI:InChI=1S/C10H13NO/c11-9-3-1-7-2-4-10(12)6-8(7)5-9/h2,4,6,9,12H,1,3,5,11H2

Upstream product

• 4133-34-0 7-methoxyl-2-tetralone 
• 37827-68-2 7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-one 
• 4003-89-8 2-amino-7-methoxy-1,2,3,4-tetrahydronaphthalene 
• 103393-75-5 1,2,3,4-tetrahydronaphthalene-2,7-diamine 
• 93-36-7 2-amino-7-hydroxynaphthalene 
• 123-51-3 i-Amyl alcohol 

Downstream Products

• 131813-11-1 N-(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)-2-hydroxy-3-(2-methoxyphenoxy)propanamine hydrochloride 
• 131813-56-4 N-(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)-2-hydroxy-3-(2-chlorophenoxy)propanamine hydrochloride 
• 131838-87-4 N-(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)-2-hydroxy-3-[2-(2-propynyloxy)phenoxy]propanamine hydrochloride 
• 131813-15-5 N-(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)-2-hydroxy-3-(2-allyloxyphenoxy)propanamine hydrochloride 

Relevant academic research and scientific papers

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.

A series of 2-aminotetralins, substituted with a methoxy or a hydroxy group on the 5- or 7-position, and with varying N-alkyl or N-arylalkyl substituents, were prepared and evaluated in binding assays for human dopamine (DA) D2, D3, and D4 receptors. Some members of this series were prepared in former studies, but were never tested in vitro with single receptor subtypes, and these were examined again. None of the tested 2-aminotetralins showed high affinity for the dopamine D4 receptor. However, a number of the 2-aminotetralins showed high affinity for both the D2 and the D3 DA receptors, as exemplified by compounds 11-15 and 21-26, while some had a reasonable selectivity for the DA D3 receptors. The affinities of the 2-aminotetralins for the D21, receptor depended on the type of radioligand (agonist or antagonist) used. The agonist affinity data, obtained by using the agonist ligand [3H]N-0437, are thought to be more relevant for calculating DA receptor subtype selectivity.

Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them

Aryloxypropanolaminotetralins with beta-antagonist activity of the formula STR1 wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group, in optically active or inactive form as well as their acid addition salts are described.A process for their preparation and pharmaceutical compositions containing the compounds of formula (i) or their pharmaceutically acceptable acid addition salts, are also described.